Abstract | BACKGROUND: STUDY DESIGN AND METHODS:
Thrombocytopenia was induced in FcγRIIb-deficient mice on B6;129S, C57BL/6, and BALB/C backgrounds, as well as splenectomized mice and control mice by platelet (PLT) antibody. PLT counts were enumerated before and after treatment with anti-CD44, red blood cell antibodies, or IVIG. RESULTS: Anti-CD44 is ineffective at inhibiting thrombocytopenia in B6;129S FcγRIIb-deficient mice but, like IVIG, is effective in splenectomized mice and FcγRIIb-deficient mice on the BALB/C and C57BL/6 background. CONCLUSION: These data suggest that 1) the B6;129S background itself is unlikely to be the sole reason for anti-CD44's inability to function in B6;129S FcγRIIb-deficient mice, 2) the simple loss of macrophage FcγRIIb expression alone is insufficient to explain anti-CD44 ameliorative function, and 3) a combination of mouse background genes in addition to FcγRIIb genetic disruption may affect the ability of anti-CD44 to function therapeutically. Similarities between IVIG and anti-CD44 mechanisms suggest that patients responsive to IVIG may also potentially respond to anti-CD44 treatment.
|
Authors | Andrew R Crow, Alaa Amash, Alan H Lazarus |
Journal | Transfusion
(Transfusion)
Vol. 55
Issue 6 Pt 2
Pg. 1492-500
(Jun 2015)
ISSN: 1537-2995 [Electronic] United States |
PMID | 25496771
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2014 AABB. |
Chemical References |
- Antibodies
- Cd44 protein, mouse
- Fcgr2b protein, mouse
- Hyaluronan Receptors
- Immunoglobulins, Intravenous
- Receptors, IgG
|
Topics |
- Animals
- Antibodies
(therapeutic use)
- Disease Models, Animal
- Gene Targeting
- Hyaluronan Receptors
(immunology)
- Immunoglobulins, Intravenous
(therapeutic use)
- Immunotherapy
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C3H
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, SCID
- Purpura, Thrombocytopenic, Idiopathic
(genetics, immunology, therapy)
- Receptors, IgG
(genetics)
- Species Specificity
|